General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0EZOEW
ADC Name
1F6-Met-Lys-AF
Drug Status
Investigative
Indication
In total 2 Indication(s)
Hodgkin lymphoma [ICD11:2B30]
Investigative
Renal cell carcinoma [ICD11:2C90]
Investigative
Structure
Antibody Name
Anti-CD70 mAb IF6
 Antibody Info 
Antigen Name
CD70 antigen (CD70)
 Antigen Info 
Payload Name
Auristatin F
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Mal-Met-Lys
 Linker Info 
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
3
ng/mL
L-428 cells
Hodgkin lymphoma
Half Maximal Inhibitory Concentration (IC50) 
4
ng/mL
Caki-1 cells
Clear cell renal cell carcinoma
Half Maximal Inhibitory Concentration (IC50) 
7
ng/mL
786-O cells
Renal cell carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 3.00 ng/mL Positive CD70 expression (CD70+++/++)
Method Description
IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model Hodgkin lymphoma L-428 cells CVCL_1361
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 4.00 ng/mL Positive CD70 expression (CD70+++/++)
Method Description
IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model Clear cell renal cell carcinoma Caki-1 cells CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 7.00 ng/mL Positive CD70 expression (CD70+++/++)
Method Description
IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model Renal cell carcinoma 786-O cells CVCL_1051
References
Ref 1 Novel Peptide Linkers for Highly Potent Antibody-Auristatin Conjugate.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.